{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T06:33:31Z","timestamp":1770532411919,"version":"3.49.0"},"reference-count":52,"publisher":"Japanese Society for Magnetic Resonance in Medicine","issue":"1","funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K07698"],"award-info":[{"award-number":["22K07698"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MRMS","magn reson med sci"],"published-print":{"date-parts":[[2026]]},"DOI":"10.2463\/mrms.mp.2025-0045","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T22:08:27Z","timestamp":1759874907000},"page":"n\/a","source":"Crossref","is-referenced-by-count":2,"title":["Diagnostic Potential of Macromolecular Proton Fraction Mapping Combined with Quantitative Susceptibility Mapping as a Subcortical Biomarker for Parkinson\u2019s Disease"],"prefix":"10.2463","volume":"25","author":[{"given":"Yasuhiro","family":"Fujiwara","sequence":"first","affiliation":[{"name":"Department of Medical Imaging Technology, Faculty of Life Sciences, Kumamoto University, Kumamoto Kumamoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"Sakae","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Omuta National Hospital, Omuta Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kumazoe","sequence":"additional","affiliation":[{"name":"Department of Radiology, National Hospital Organization Omuta National Hospital, Omuta Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouta","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Radiology, National Hospital Organization Omuta National Hospital, Omuta Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Hirakawa","sequence":"additional","affiliation":[{"name":"Department of Radiology, National Hospital Organization Omuta National Hospital, Omuta Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohito","family":"Kan","sequence":"additional","affiliation":[{"name":"Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging Technology, Faculty of Life Sciences, Kumamoto University, Kumamoto Kumamoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Kitajima","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging Technology, Faculty of Life Sciences, Kumamoto University, Kumamoto Kumamoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1295","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D. The patients\u2019 perception of prodromal symptoms before the initial diagnosis of Parkinson\u2019s disease. Mov Disord 2011; 26:653\u2013658.","DOI":"10.1002\/mds.23499"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Fearnley JM, Lees AJ. Ageing and Parkinson\u2019s disease: Substantia nigra regional selectivity. Brain 1991; 114:2283\u20132301.","DOI":"10.1093\/brain\/114.5.2283"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Noyce AJ, Lees AJ, Schrag A-E. The prediagnostic phase of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 2016; 87:871\u2013878.","DOI":"10.1136\/jnnp-2015-311890"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Benazzouz A, Mamad O, Abedi P, Bouali-Benazzouz R, Chetrit J. Involvement of dopamine loss in extrastriatal basal ganglia nuclei in the pathophysiology of Parkinson\u2019s disease. Front Aging Neurosci 2014; 6:87.","DOI":"10.3389\/fnagi.2014.00087"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Rommelfanger KS, Wichmann T. Extrastriatal dopaminergic circuits of the basal ganglia. Front Neuroanat 2010; 4:139.","DOI":"10.3389\/fnana.2010.00139"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wu T, Wang J, Wang C, et al. Basal ganglia circuits changes in Parkinson\u2019s disease patients. Neurosci Lett 2012; 524:55\u201359.","DOI":"10.1016\/j.neulet.2012.07.012"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Langkammer C, Pirpamer L, Seiler S, et al. Quantitative susceptibility mapping in Parkinson\u2019s disease. PLoS One 2016; 11:e0162460.","DOI":"10.1371\/journal.pone.0162460"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Guan X, Lancione M, Ayton S, Dusek P, Langkammer C, Zhang M. Neuroimaging of Parkinson\u2019s disease by quantitative susceptibility mapping. Neuroimage 2024; 289:120547.","DOI":"10.1016\/j.neuroimage.2024.120547"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Uchida Y, Kan H, Sakurai K, et al. Magnetic susceptibility associates with dopaminergic deficits and cognition in Parkinson\u2019s disease. Mov Disord 2020; 35:1396\u20131405.","DOI":"10.1002\/mds.28077"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tan S, Hartono S, Welton T, et al. Utility of quantitative susceptibility mapping and diffusion kurtosis imaging in the diagnosis of early Parkinson\u2019s disease. Neuroimage Clin 2021; 32:102831.","DOI":"10.1016\/j.nicl.2021.102831"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Chen Q, Chen Y, Zhang Y, et al. Iron deposition in Parkinson\u2019s disease by quantitative susceptibility mapping. BMC Neurosci 2019; 20:23.","DOI":"10.1186\/s12868-019-0505-9"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sj\u00f6str\u00f6m H, Granberg T, Westman E, Svenningsson P. Quantitative susceptibility mapping differentiates between parkinsonian disorders. Parkinsonism Relat Disord 2017; 44:51\u201357.","DOI":"10.1016\/j.parkreldis.2017.08.029"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ndayisaba A, Kaindlstorfer C, Wenning GK. Iron in neurodegeneration\u2014cause or consequence? Front Neurosci 2019; 13:180.","DOI":"10.3389\/fnins.2019.00180"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Levi S, Ripamonti M, Moro AS, Cozzi A. Iron imbalance in neurodegeneration. Mol Psychiatry 2024; 29:1139\u20131152.","DOI":"10.1038\/s41380-023-02399-z"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yarnykh VL. Time-efficient, high-resolution, whole brain three-dimensional macromolecular proton fraction mapping. Magn Reson Med 2016; 75:2100\u20132106.","DOI":"10.1002\/mrm.25811"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kisel AA, Naumova AV, Yarnykh VL. Macromolecular proton fraction as a myelin biomarker: Principles, validation, and applications. Front Neurosci 2022; 16:819912.","DOI":"10.3389\/fnins.2022.819912"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yarnykh VL, Prihod\u2019ko IY, Savelov AA, Korostyshevskaya AM. Quantitative assessment of normal fetal brain myelination using fast macromolecular proton fraction mapping. AJNR Am J Neuroradiol 2018; 39:1341\u20131348.","DOI":"10.3174\/ajnr.A5668"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yarnykh VL. Fast macromolecular proton fraction mapping from a single off-resonance magnetization transfer measurement. Magn Reson Med 2012; 68:166\u2013178.","DOI":"10.1002\/mrm.23224"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Samson RS, Wheeler-Kingshott CAM, Symms MR, Tozer DJ, Tofts PS. A simple correction for B1 field errors in magnetization transfer ratio measurements. Magn Reson Imaging 2006; 24:255\u2013263.","DOI":"10.1016\/j.mri.2005.10.025"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. \u00d6zbay PS, Deistung A, Feng X, Nanz D, Reichenbach JR, Schweser F. A comprehensive numerical analysis of background phase correction with V-SHARP. NMR Biomed 2017; 30:e3550.","DOI":"10.1002\/nbm.3550"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kan H, Uchida Y, Ueki Y, et al. R2* relaxometry analysis for mapping of white matter alteration in Parkinson\u2019s disease with mild cognitive impairment. Neuroimage Clin 2022; 33:102938.","DOI":"10.1016\/j.nicl.2022.102938"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Wu B, Li W, Avram AV, Gho S-M, Liu C. Fast and tissue-optimized mapping of magnetic susceptibility and T2* with multi-echo and multi-shot spirals. Neuroimage 2012; 59:297\u2013305.","DOI":"10.1016\/j.neuroimage.2011.07.019"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Uchida Y, Kan H, Sakurai K, et al. Voxel-based quantitative susceptibility mapping in Parkinson\u2019s disease with mild cognitive impairment. Mov Disord 2019; 34:1164\u20131173.","DOI":"10.1002\/mds.27717"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kan H, Uchida Y, Arai N, et al. Simultaneous voxel-based magnetic susceptibility and morphometry analysis using magnetization-prepared spoiled turbo multiple gradient echo. NMR Biomed 2020; 33:e4272.","DOI":"10.1002\/nbm.4272"},{"key":"25","unstructured":"25. Avants BB, Tustison NJ, Johnson HJ. ANTs by stnava, 2009. https:\/\/stnava.github.io\/ANTs\/ (Accessed: Jan 23, 2025)."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Pauli WM, Nili AN, Tyszka JM. A high-resolution probabilistic in vivo atlas of human subcortical brain nuclei. Sci Data 2018; 5:180063.","DOI":"10.1038\/sdata.2018.63"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Braak H, Del Tredici K, R\u00fcb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 2003; 24:197\u2013211.","DOI":"10.1016\/S0197-4580(02)00065-9"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Jellinger KA. Neuropathology of sporadic Parkinson\u2019s disease: Evaluation and changes of concepts. Mov Disord 2012; 27:8\u201330.","DOI":"10.1002\/mds.23795"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Dickson DW. Parkinson\u2019s disease and parkinsonism: Neuropathology. Cold Spring Harb Perspect Med 2012; 2:a009258.","DOI":"10.1101\/cshperspect.a009258"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Khodanovich MY, Sorokina IV, Glazacheva VY, et al. Histological validation of fast macromolecular proton fraction mapping as a quantitative myelin imaging method in the cuprizone demyelination model. Sci Rep 2017; 7:46686.","DOI":"10.1038\/srep46686"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Underhill HR, Rostomily RC, Mikheev AM, Yuan C, Yarnykh VL. Fast bound pool fraction imaging of the in vivo rat brain: Association with myelin content and validation in the C6 glioma model. Neuroimage 2011; 54:2052\u20132065.","DOI":"10.1016\/j.neuroimage.2010.10.065"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Yarnykh VL, Krutenkova EP, Aitmagambetova G, et al. Iron-insensitive quantitative assessment of subcortical gray matter demyelination in multiple sclerosis using the macromolecular proton fraction. AJNR Am J Neuroradiol 2018; 39:618\u2013625.","DOI":"10.3174\/ajnr.A5542"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Boshkovski T, Cohen-Adad J, Misic B, et al. The myelin-weighted connectome in Parkinson\u2019s disease. Mov Disord 2022; 37:724\u2013733.","DOI":"10.1002\/mds.28891"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Kamagata K, Hatano T, Okuzumi A, et al. Neurite orientation dispersion and density imaging in the substantia nigra in idiopathic Parkinson disease. Eur Radiol 2016; 26:2567\u20132577.","DOI":"10.1007\/s00330-015-4066-8"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Zhang H, Schneider T, Wheeler-Kingshott CA, Alexander DC. NODDI: Practical in vivo neurite orientation dispersion and density imaging of the human brain. Neuroimage 2012; 61:1000\u20131016.","DOI":"10.1016\/j.neuroimage.2012.03.072"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Naumova AV, Akulov AE, Khodanovich MY, Yarnykh VL. High-resolution three-dimensional macromolecular proton fraction mapping for quantitative neuroanatomical imaging of the rodent brain in ultra-high magnetic fields. Neuroimage 2017; 147:985\u2013993.","DOI":"10.1016\/j.neuroimage.2016.09.036"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Acosta-Cabronero J, Cardenas-Blanco A, Betts MJ, et al. The whole-brain pattern of magnetic susceptibility perturbations in Parkinson\u2019s disease. Brain 2017; 140:118\u2013131.","DOI":"10.1093\/brain\/aww278"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Barbosa JHO, Santos AC, Tumas V, et al. Quantifying brain iron deposition in patients with Parkinson\u2019s disease using quantitative susceptibility mapping, R2 and R2*. Magn Reson Imaging 2015; 33:559\u2013565.","DOI":"10.1016\/j.mri.2015.02.021"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 2014; 13:1045\u20131060.","DOI":"10.1016\/S1474-4422(14)70117-6"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Takahashi H, Watanabe Y, Tanaka H, et al. Comprehensive MRI quantification of the substantia nigra pars compacta in Parkinson\u2019s disease. Eur J Radiol 2018; 109:48\u201356.","DOI":"10.1016\/j.ejrad.2018.06.024"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Takahashi H, Watanabe Y, Tanaka H, et al. Quantifying changes in nigrosomes using quantitative susceptibility mapping and neuromelanin imaging for the diagnosis of early-stage Parkinson\u2019s disease. Br J Radiol 2018; 91:20180037.","DOI":"10.1259\/bjr.20180037"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Guan X, Zhang Y, Wei H, et al. Iron-related nigral degeneration influences functional topology mediated by striatal dysfunction in Parkinson\u2019s disease. Neurobiol Aging 2019; 75:83\u201397.","DOI":"10.1016\/j.neurobiolaging.2018.11.013"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. P\u00e9ran P, Barbagallo G, Nemmi F, et al. MRI supervised and unsupervised classification of Parkinson\u2019s disease and multiple system atrophy. Mov Disord 2018; 33:600\u2013608.","DOI":"10.1002\/mds.27307"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Braak H, Ghebremedhin E, R\u00fcb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res 2004; 318:121\u2013134.","DOI":"10.1007\/s00441-004-0956-9"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Del Tredici K, Braak H. Review: Sporadic Parkinson\u2019s disease: Development and distribution of \u03b1-synuclein pathology. Neuropathol Appl Neurobiol 2016; 42:33\u201350.","DOI":"10.1111\/nan.12298"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Zucca FA, Segura-Aguilar J, Ferrari E, et al. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson\u2019s disease. Prog Neurobiol 2017; 155:96\u2013119.","DOI":"10.1016\/j.pneurobio.2015.09.012"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci 2017; 18:435\u2013450.","DOI":"10.1038\/nrn.2017.62"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Mueller K, Urgo\u0161\u00edk D, Ballarini T, et al. Differential effects of deep brain stimulation and levodopa on brain activity in Parkinson\u2019s disease. Brain Commun 2020; 2:fcaa005.","DOI":"10.1093\/braincomms\/fcaa005"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Tessitore A, Esposito F, Vitale C, et al. Default-mode network connectivity in cognitively unimpaired patients with Parkinson disease. Neurology 2012; 79:2226\u20132232.","DOI":"10.1212\/WNL.0b013e31827689d6"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Krajcovicova L, Mikl M, Marecek R, Rektorova I. The default mode network integrity in patients with Parkinson\u2019s disease is levodopa equivalent dose-dependent. J Neural Transm (Vienna) 2012; 119:443\u2013454.","DOI":"10.1007\/s00702-011-0723-5"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Prodoehl J, Burciu RG, Vaillancourt DE. Resting state functional magnetic resonance imaging in Parkinson\u2019s disease. Curr Neurol Neurosci Rep 2014; 14:448.","DOI":"10.1007\/s11910-014-0448-6"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Atkinson-Clement C, Pinto S, Eusebio A, Coulon O. Diffusion tensor imaging in Parkinson\u2019s disease: Review and meta-analysis. Neuroimage Clin 2017; 16:98\u2013110.","DOI":"10.1016\/j.nicl.2017.07.011"}],"container-title":["Magnetic Resonance in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mrms\/25\/1\/25_mp.2025-0045\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T03:57:44Z","timestamp":1769831864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mrms\/25\/1\/25_mp.2025-0045\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2463\/mrms.mp.2025-0045","relation":{},"ISSN":["1347-3182","1880-2206"],"issn-type":[{"value":"1347-3182","type":"print"},{"value":"1880-2206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"mp.2025-0045"}}